Chief Executive Officer

David Chiswell joined Nabriva Therapeutics in March 2009 as Chief Executive Officer. After a career as a research scientist in both the UK and the US and nine years working in scientific management at Amersham International, David was co-founder of Cambridge Antibody Technology (CAT) in 1990. He was responsible for operational management from 1990 to 2002 including as CEO from 1996 to 2002. CAT listed on the London Stock exchange in April 1997 and Nasdaq in June 2001. Since leaving CAT in March 2002 David has been focusing on the development of early stage biotechnology companies including positions as non-executive Chairman of Sosei Ltd, Arrow Therapeutics Ltd, and Daniolabs Ltd and as a director of Arakis Ltd. David is currently Executive Chairman of Albireo Ltd and is an advisor to Nomura Phase IV ventures. David is a past Chairman of the UK’s BioIndustry association (BIA) and remains on their board. In 2006 he was awarded the OBE by HM Queen for services to the biotechnology industry.